Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.80
+1.84 (5.58%)
At close: Apr 2, 2026, 4:00 PM EDT
34.73
-0.07 (-0.20%)
After-hours: Apr 2, 2026, 7:58 PM EDT
Viking Therapeutics Employees
Viking Therapeutics had 53 employees as of December 31, 2025. The number of employees increased by 17 or 47.22% compared to the previous year.
Employees
53
Change
17
Growth
47.22%
Revenue / Employee
n/a
Profits / Employee
-$6,785,642
Market Cap
4.02B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| ACADIA Pharmaceuticals | 798 |
| Corcept Therapeutics | 730 |
| Crinetics Pharmaceuticals | 594 |
| Amicus Therapeutics | 511 |
| Structure Therapeutics | 220 |
| Edgewise Therapeutics | 146 |
| Spyre Therapeutics | 102 |
VKTX News
- 8 days ago - Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - PRNewsWire
- 24 days ago - Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 4 weeks ago - Viking Therapeutics to Participate at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Viking Therapeutics Stock Gains Amid Obesity Drug Buzz - Benzinga
- 6 weeks ago - Viking Therapeutics: Full-Speed Ahead - Seeking Alpha
- 7 weeks ago - Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential - Seeking Alpha
- 7 weeks ago - Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Viking Therapeutics plans to advance oral obesity drug to late-stage trial - Reuters